AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
WALTHAM, Mass., March 28, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
